Search IconSearch

Heart & Vascular Clinical Trials

From prevention and pacing to stenting and surgery


Here are a few of the many clinical research trials underway in Cleveland Clinic’s Sydell and Arnold Miller Family Heart & Vascular Institute. For information on enrolling a patient in these or other trials, call 216.445.3608.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Cardiothoracic Surgery

PERIGON: Medtronic Pericardial Surgical Aortic Valve Replacement Pivotal Trial
Site PI: Joseph Sabik, MD (also national PI)
Description: Nonrandomized phase 3 trial evaluating the safety and effectiveness of the Medtronic Model 400 aortic valve bioprosthesis
Population: Patients requiring replacement of their native or prosthetic aortic valve (with or without concomitant procedures such as CABG surgery)
Sponsor: Medtronic Cardiovascular

Clinical Investigation of the Perceval S Sutureless Heart Valve
Site PI: Eric Roselli, MD
Description: Nonrandomized prospective study of the safety and effectiveness of the Perceval S heart valve to replace a diseased or dysfunctional native or prosthetic aortic valve
Population: Patients scheduled to undergo planned aortic valve replacement
Sponsor: Sorin Group USA

eMESH I: Study of External Saphenous Vein Support Using eSVS® Mesh in CABG Surgery
Site PI: Joseph Sabik, MD
Description: Randomized prospective study to assess the feasibility, initial safety and performance of the eSVS Mesh as an external vein support device for use over saphenous vein grafts (SVGs) during CABG surgery. Each enrollee receives an SVG without the mesh (control) and an SVG with the mesh (treatment).
Population: Patients requiring CABG surgery with SVGs to the right coronary artery system and the left circumflex artery system, with ≥ 70 percent stenosis in each system
Sponsor: Kips Bay Medical


LEADLESS II IDE: Safety and Effectiveness Trial for the Nanostim™ Leadless Pacemaker
Site PI: Daniel Cantillon, MD
Description: Phase 3 study of the safety and effectiveness of the Nanostim leadless pacemaker
Population: Patients with indications for a VVI pacemaker
Sponsor: St. Jude Medical

Micra Transcatheter Pacing Study
Site PI: Bruce Wilkoff, MD
Description: Phase 3 study to evaluate the safety and efficacy of the leadless Micra™ Transcatheter Pacing System and assess its long-term performance
Population: Patients with a class I or II indication for implantation of a single-chamber ventricular pacemaker
Sponsor: Medtronic Cardiac Rhythm Disease Management


reMARQable: nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
Site PI: Bruce Lindsay, MD
Description: Randomized phase 3 trial evaluating the safety and effectiveness of the nMARQ Catheter System vs. ThermoCool® Navigation Catheters in treating drug-refractory symptomatic paroxysmal atrial fibrillation (AF)
Population: Patients with symptomatic paroxysmal AF who have had at least one AF episode in the prior year and failure of at least one antiarrhythmic drug
Sponsor: Biosense Webster

Heart Failure

FIGHT: Functional Impact of GLP-1 for Heart Failure Treatment
Site PI: Wilson Tang, MD
Description: Randomized, double-blind phase 2 trial testing whether treatment with a subcutaneously delivered GLP-1 agonist in the period after acute heart failure syndrome discharge is associated with greater clinical stability (measured by a composite clinical endpoint) at six months compared with placebo
Population: Patients recently hospitalized for heart failure with an LVEF < 40 percent Sponsors: Duke University and NHLBI

GUIDE-IT: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Site PI: Wilson Tang, MD
Description: Randomized open-label trial to determine the efficacy of a strategy of biomarker-guided therapy compared with usual care in high-risk patients with left ventricular systolic dysfunction
Population: Heart failure patients with a recent LVEF < 40 percent and recent hospitalization or ED visit for heart failure
Sponsors: Duke University and NHLBI

NEAT: Nitrate’s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction
Site PI: Wilson Tang, MD
Description: Randomized, double-blind, placebo-controlled crossover study assessing the effect of isosorbide mononitrate with upward dose titration on activity tolerance as assessed by accelerometry
Population: Heart failure patients with preserved ejection fraction
Sponsors: Duke University and NHLBI


HCMR: Novel Markers of Prognosis in Hypertrophic Cardiomyopathy
Site PI: Milind Desai, MD
Description: Patient registry study to develop a predictive model of cardiovascular outcomes in hypertrophic cardiomyopathy (HCM) by using data mining to identify demographic, clinical and novel cardiovascular magnetic resonance, genetic and biomarker variables associated with outcomes
Population: Adults up to age 65 with an established diagnosis of HCM defined as unexplained left ventricular hypertrophy
Sponsors: University of Virginia and NHLBI


VANISH: Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM
Site PI: Harry Lever, MD
Description: Randomized, double-blind, placebo-controlled phase 2 trial assessing the safety and efficacy of valsartan in attenuating disease evolution in early hypertrophic cardiomyopathy (HCM)
Population: Patients with a pathogenic or likely pathogenic HCM sarcomere mutation
Sponsors: New England Research Institutes and NHLBI

Interventional Cardiology

ABSORB IV: A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold, in the Treatment of Subjects with De Novo Native Coronary Artery Lesions
Site PI: Russell Raymond, DO
Description: Randomized, controlled, single-blind evaluation of the Absorb BVS everolimus-eluting bioresorbable vascular scaffold compared with XIENCE stents for the treatment of denovo native coronary artery lesions
Population: Patients with de novo native coronary artery lesions
Sponsor: Abbott Vascular

SALUS: The Direct Flow Medical Transcatheter Aortic Valve Replacement System: A U.S. Pivotal Trial
Site PI: Samir Kapadia, MD
Description: Open-label study to assess the safety and effectiveness of the Direct Flow Medical aortic valve system for patients with severe aortic stenosis who are not well enough to undergo surgical repair
Population: Patients with severe symptomatic aortic stenosis at high risk or deemed not suitable for surgery following evaluation by a cardiac surgeon
Sponsor: Direct Flow Medical

Preventive Cardiology

GAUSS-3: Trial of Patients with Statin Intolerance Randomized to PCSK9 vs. Zetia
Site PI: Michael Rocco, MD
Description: Randomized, double-blind, controlled phase 3 study of AMG 145 (evolocumab) in statin-intolerant individuals with dyslipidemia to assess side effects and efficacy in lowering LDL cholesterol and increasing HDL cholesterol
Population: Patients ages 18 to 80 who are not at goal LDL cholesterol, have fasting triglycerides ≤ 400 mg/dL, have a history of intolerance to at least two statins, and currently are not on a statin or are on a stable low dose
Sponsor: Amgen

GRADY: Gut Flora Metabolite Reduction After Dietary Intervention
Site PIs: Wilson Tang, MD, and Stanley Hazen, MD, PhD
Description: Randomized, open-label phase 1/2 study investigating the ability of dietary intervention to modulate TMAO levels with and without TMAO levels being provided to subjects for guidance
Population: Patients with elevated TMAO metabolizers (> 5 μM), based on a screening test, who are willing to follow a modified Mediterranean diet for 12 weeks
Sponsor: Cleveland Clinic


STRENGTH: Outcomes Study to Assess Statin Residual Risk Reduction with Epanova® in High CV Risk Patients with Hypertriglyceridemia
Site PI: Michael Rocco, MD
Description: Double-blind, controlled, parallel-group phase 3 study randomizing 13,000 patients to either Epanova (omega-3 carboxylic acids) plus statin therapy or corn oil plus statin therapy for three to five years to assess for major adverse cardiovascular events
Population: Eligible adults considered to be at high risk for atherosclerotic cardiovascular disease
Sponsor: AstraZeneca, with Cleveland Clinic as collaborator

Vascular Medicine

ATTRACT: Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis
Site PI: Heather Gornik, MD
Description: Randomized open-label study to determine whether pharmacomechanical catheter-directed thrombolysis prevents post-thrombotic syndrome and improves quality of life in patients with DVT compared with optimal standard DVT therapy alone
Population: Patients ages 16 through 75 with symptomatic proximal DVT involving the iliac, common femoral and/or femoral veins
Sponsor: Washington University School of Medicine

PRYME: Prospective Registry of Young Women with MI: Evaluating the Prevalence and Long-term Impact of Nonatherosclerotic CAD
Site PI: Heather Gornik, MD
Description: Prospective observational registry study to evaluate the long-term outcome of young women with nonatherosclerotic coronary artery disease (CAD) relative to those with atherosclerotic CAD over five years of follow up
Population: Women 55 or younger with a troponin-positive acute coronary syndrome who have a coronary angiogram
Sponsors: Cardiology Research UBC and University of British Columbia

Vascular Surgery

EVAS IDE: Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System
Site PI: Daniel Clair, MD
Description: Prospective single-arm study assessing the safety and effectiveness of the investigational Nellix System for the endovascular repair of infrarenal abdominal aortic aneurysms
Population: Patients with abdominal aortic aneurysms
Sponsor: Endologix

Lutonix® Drug Coated Balloon Versus Standard Balloon Angioplasty for Treatment of Below-the-Knee Arteries
Site PI: Sean Lyden, MD
Description: Randomized single-blind study comparing the Lutonix Drug Coated Balloon with standard balloon angioplasty for safety and efficacy in the treatment of stenosis or occlusion of native below-the-knee arteries
Population: Patients with stenosis or occlusion of native below-the-knee arteries
Sponsor: C.R. Bard


Related Articles

New Guideline Helps Evaluate Risk in Patients With Chest Pain

Further acute testing not needed if ECG and high-sensitivity troponin are negative

New Head of Vascular Medicine Looks to Enhance Collaborative Caregiving

Scott Cameron, MD, PhD, also brings wide-ranging research interests to bear

Stroke Risk in Cardiac Surgery: New Guidance for Averting a Dreaded Complication

AHA statement is first comprehensive document on perioperative stroke reduction

20-HVI-1898975 Singh_Guidelines on CV imaging in athletes_CQD_650x450_993744768
First Formal Guidance Issued on Multimodality Cardiac Imaging in Young Athletes

Recommendations help distinguish exercise-induced remodeling from pathology

Trio of Studies at Virtual HRS Meeting Showcase Catheter Ablation Advances

Pushing the envelope in ablation of atrial fibrillation, ventricular tachycardia